---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-25-000054"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:08:01.710836+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)

## Summary
- Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.
- GAAP EPS $2.65 vs $1.38 (+92%); GAAP operating income $2.7B, margin 30.3%.
- Non-GAAP EPS $6.02 vs $4.97 (+21%); non-GAAP operating margin 48.9%.
- Free cash flow $1.9B in Q2, down from $2.2B, reflecting deferred 2024 tax payments and higher capex.
- Fifteen products had double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, TAVNEOS.

## SEC filing metadata
- accession: 0000318154-25-000054
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/0000318154-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-25-000054
- JSON: https://secwatch.observer/filing/0000318154-25-000054.json
- Plain text: https://secwatch.observer/filing/0000318154-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.